Despite mostly unsuccessful clinical trials, recent findings that cDC1s play a critical role in cross-priming tumor-specific CD8 T cells and in determining the anti-tumor efficacy of cancer immunotherapies [36,37,38,39,40], has reignited the efforts to further develop/refine DC-based vaccines either as monotherapies or combined therapies. This evidence concerns the gene CD8A and cancer.